Neurology News

The FDA has approved an expanded indication of Boston Scientific’s spinal cord stimulation system that treats painful diabetic peripheral neuropathy, a complication of diabetes that often affects the lower extremities.

Hospitalized patients with multisystem inflammatory syndrome in children — or MIS-C —are far more likely to experience shock than those hospitalized with Kawasaki disease, according to a study.

Ocrevus infusions were effective in halting disease activity in Black and Hispanic individuals with relapsing forms of multiple sclerosis after 1 year, according to a study presented at ECTRIMS 2023.

Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.

Physicians of all specialties are likely aware of health savings accounts and their use by patients and doctors alike to pay for health-related expenses.

Presence of cytokine proteins in those with neuromyelitis optica spectrum disorder was linked to disease activity, which was lessened after treatment with inebilizumab, according to a presentation from ECTRIMS 2023.

For those with relapsing-remitting multiple sclerosis, treatment with vidofludimus calcium led to reductions in neurofilament light chain biomarkers as early as week 6 compared with placebo, according to a presentation at ECTRIMS 2023.

A Southern California biopharmaceutical company has announced positive data from a phase 1/2 clinical trial of its proprietary monoclonal antibody, AOC 1001, for those with myotonic dystrophy type 1.

In those with traumatic brain injury, patterns of two blood-based biomarkers were similar between the sexes, with significantly higher concentrations of one in male patients compared with female patients, according to research from Nature.

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.